A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer

Kenichi Chikamori, Daizo Kishino, Nagio Takigawa, Katsuyuki Hotta, Naoyuki Nogami, Haruhito Kamei, Shoichi Kuyama, Kenichi Gemba, Mitsuhiro Takemoto, Susumu Kanazawa, Hiroshi Ueoka, Yoshihiko Segawa, Saburo Takata, Masahiro Tabata, Katsuyuki Kiura, Mitsune Tanimoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A combination of S-1, a newly developed oral 5-fluorouracil derivative, and cisplatin is reported to show anti-tumour activity against advanced non-small cell lung cancer (NSCLC). Because S-1 shows synergistic effects with radiation, we conducted a phase I study to evaluate the maximum tolerated doses (MTDs), recommended doses (RDs), and dose-limiting toxicities (DLTs) of cisplatin and S-1 when combined with concurrent thoracic radiation (total dose of 60 Gy with 2 Gy per daily fraction) in patients with locally advanced NSCLC. Chemotherapy consisted of two 4-week cycles of cisplatin administered on days 1 and 8, and S-1 administered on days 1-14. S-1/cisplatin dosages (mg/m2/day) were escalated as follows: 60/30, 60/40, 70/40, 80/40 and 80/50. Twenty-two previously untreated patients were enrolled. The MTDs and RDs for S-1/cisplatin were 80/50 and 80/40, respectively. DLTs included febrile neutropaenia, thrombocytopaenia, bacterial pneumonia and delayed second cycle of chemotherapy. No patient experienced radiation pneumonitis > grade 2 and only one patient experienced grade 3 radiation oesophagitis. The overall response rate was 86.4% with a median survival time of 24.4 months. These results indicate that combination cisplatin-S-1 chemotherapy with concurrent thoracic radiation would be a feasible treatment option and a phase II study is currently under way.

Original languageEnglish
Pages (from-to)74-79
Number of pages6
JournalLung Cancer
Volume65
Issue number1
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Thorax
Radiation
Drug Therapy
Maximum Tolerated Dose
Radiation Pneumonitis
Bacterial Pneumonia
Esophagitis
Radiation Effects
Fluorouracil
S 1 (combination)
Fever
Survival
Neoplasms

Keywords

  • Cisplatin
  • Non-small cell lung cancer
  • Radiation
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. / Chikamori, Kenichi; Kishino, Daizo; Takigawa, Nagio; Hotta, Katsuyuki; Nogami, Naoyuki; Kamei, Haruhito; Kuyama, Shoichi; Gemba, Kenichi; Takemoto, Mitsuhiro; Kanazawa, Susumu; Ueoka, Hiroshi; Segawa, Yoshihiko; Takata, Saburo; Tabata, Masahiro; Kiura, Katsuyuki; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 65, No. 1, 07.2009, p. 74-79.

Research output: Contribution to journalArticle

Chikamori, K, Kishino, D, Takigawa, N, Hotta, K, Nogami, N, Kamei, H, Kuyama, S, Gemba, K, Takemoto, M, Kanazawa, S, Ueoka, H, Segawa, Y, Takata, S, Tabata, M, Kiura, K & Tanimoto, M 2009, 'A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer', Lung Cancer, vol. 65, no. 1, pp. 74-79. https://doi.org/10.1016/j.lungcan.2008.10.019
Chikamori, Kenichi ; Kishino, Daizo ; Takigawa, Nagio ; Hotta, Katsuyuki ; Nogami, Naoyuki ; Kamei, Haruhito ; Kuyama, Shoichi ; Gemba, Kenichi ; Takemoto, Mitsuhiro ; Kanazawa, Susumu ; Ueoka, Hiroshi ; Segawa, Yoshihiko ; Takata, Saburo ; Tabata, Masahiro ; Kiura, Katsuyuki ; Tanimoto, Mitsune. / A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. In: Lung Cancer. 2009 ; Vol. 65, No. 1. pp. 74-79.
@article{6c24b08252e946379ef4bf6227245fa3,
title = "A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer",
abstract = "A combination of S-1, a newly developed oral 5-fluorouracil derivative, and cisplatin is reported to show anti-tumour activity against advanced non-small cell lung cancer (NSCLC). Because S-1 shows synergistic effects with radiation, we conducted a phase I study to evaluate the maximum tolerated doses (MTDs), recommended doses (RDs), and dose-limiting toxicities (DLTs) of cisplatin and S-1 when combined with concurrent thoracic radiation (total dose of 60 Gy with 2 Gy per daily fraction) in patients with locally advanced NSCLC. Chemotherapy consisted of two 4-week cycles of cisplatin administered on days 1 and 8, and S-1 administered on days 1-14. S-1/cisplatin dosages (mg/m2/day) were escalated as follows: 60/30, 60/40, 70/40, 80/40 and 80/50. Twenty-two previously untreated patients were enrolled. The MTDs and RDs for S-1/cisplatin were 80/50 and 80/40, respectively. DLTs included febrile neutropaenia, thrombocytopaenia, bacterial pneumonia and delayed second cycle of chemotherapy. No patient experienced radiation pneumonitis > grade 2 and only one patient experienced grade 3 radiation oesophagitis. The overall response rate was 86.4{\%} with a median survival time of 24.4 months. These results indicate that combination cisplatin-S-1 chemotherapy with concurrent thoracic radiation would be a feasible treatment option and a phase II study is currently under way.",
keywords = "Cisplatin, Non-small cell lung cancer, Radiation, S-1",
author = "Kenichi Chikamori and Daizo Kishino and Nagio Takigawa and Katsuyuki Hotta and Naoyuki Nogami and Haruhito Kamei and Shoichi Kuyama and Kenichi Gemba and Mitsuhiro Takemoto and Susumu Kanazawa and Hiroshi Ueoka and Yoshihiko Segawa and Saburo Takata and Masahiro Tabata and Katsuyuki Kiura and Mitsune Tanimoto",
year = "2009",
month = "7",
doi = "10.1016/j.lungcan.2008.10.019",
language = "English",
volume = "65",
pages = "74--79",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer

AU - Chikamori, Kenichi

AU - Kishino, Daizo

AU - Takigawa, Nagio

AU - Hotta, Katsuyuki

AU - Nogami, Naoyuki

AU - Kamei, Haruhito

AU - Kuyama, Shoichi

AU - Gemba, Kenichi

AU - Takemoto, Mitsuhiro

AU - Kanazawa, Susumu

AU - Ueoka, Hiroshi

AU - Segawa, Yoshihiko

AU - Takata, Saburo

AU - Tabata, Masahiro

AU - Kiura, Katsuyuki

AU - Tanimoto, Mitsune

PY - 2009/7

Y1 - 2009/7

N2 - A combination of S-1, a newly developed oral 5-fluorouracil derivative, and cisplatin is reported to show anti-tumour activity against advanced non-small cell lung cancer (NSCLC). Because S-1 shows synergistic effects with radiation, we conducted a phase I study to evaluate the maximum tolerated doses (MTDs), recommended doses (RDs), and dose-limiting toxicities (DLTs) of cisplatin and S-1 when combined with concurrent thoracic radiation (total dose of 60 Gy with 2 Gy per daily fraction) in patients with locally advanced NSCLC. Chemotherapy consisted of two 4-week cycles of cisplatin administered on days 1 and 8, and S-1 administered on days 1-14. S-1/cisplatin dosages (mg/m2/day) were escalated as follows: 60/30, 60/40, 70/40, 80/40 and 80/50. Twenty-two previously untreated patients were enrolled. The MTDs and RDs for S-1/cisplatin were 80/50 and 80/40, respectively. DLTs included febrile neutropaenia, thrombocytopaenia, bacterial pneumonia and delayed second cycle of chemotherapy. No patient experienced radiation pneumonitis > grade 2 and only one patient experienced grade 3 radiation oesophagitis. The overall response rate was 86.4% with a median survival time of 24.4 months. These results indicate that combination cisplatin-S-1 chemotherapy with concurrent thoracic radiation would be a feasible treatment option and a phase II study is currently under way.

AB - A combination of S-1, a newly developed oral 5-fluorouracil derivative, and cisplatin is reported to show anti-tumour activity against advanced non-small cell lung cancer (NSCLC). Because S-1 shows synergistic effects with radiation, we conducted a phase I study to evaluate the maximum tolerated doses (MTDs), recommended doses (RDs), and dose-limiting toxicities (DLTs) of cisplatin and S-1 when combined with concurrent thoracic radiation (total dose of 60 Gy with 2 Gy per daily fraction) in patients with locally advanced NSCLC. Chemotherapy consisted of two 4-week cycles of cisplatin administered on days 1 and 8, and S-1 administered on days 1-14. S-1/cisplatin dosages (mg/m2/day) were escalated as follows: 60/30, 60/40, 70/40, 80/40 and 80/50. Twenty-two previously untreated patients were enrolled. The MTDs and RDs for S-1/cisplatin were 80/50 and 80/40, respectively. DLTs included febrile neutropaenia, thrombocytopaenia, bacterial pneumonia and delayed second cycle of chemotherapy. No patient experienced radiation pneumonitis > grade 2 and only one patient experienced grade 3 radiation oesophagitis. The overall response rate was 86.4% with a median survival time of 24.4 months. These results indicate that combination cisplatin-S-1 chemotherapy with concurrent thoracic radiation would be a feasible treatment option and a phase II study is currently under way.

KW - Cisplatin

KW - Non-small cell lung cancer

KW - Radiation

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=67349205897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349205897&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2008.10.019

DO - 10.1016/j.lungcan.2008.10.019

M3 - Article

C2 - 19056143

AN - SCOPUS:67349205897

VL - 65

SP - 74

EP - 79

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -